PM-TW-FFV-PPTX-250091 | Date of preparation: 2025.08
Trademarks are owned by or licensed to the GSK group of companies
Relvar Ellipta was developed in collaboration with INNOVIVA.
不良事件通報程序:(02)23126836/oax40892@gsk.com
葛蘭素史克藥廠地址:100台北市忠孝西路一段66號23樓
Intended for Taiwan Healthcare Professionals only

Meet the Asthma Expert
Taiwan Tour.
August & September. 2025

Address the Early SITT Concept in Asthma treatment vs "Flexible" Regimen
: Focus on Clinical Remission

Hironori Sagara, M.D., Ph.D.

Professor and Director
Showa Medical University Hospital
Department of Medicine, Division of Respiratory Medicine
and Allergology, Showa Medical University, School of Medicine

Conclusion

The definition of clinical remission is a good starting point and begins to suggest the possibility of treating asthma in the same way as many other chronic diseases.

The initial definition is necessary to identify the appropriate treatment and its sequence of use.

I believe Trelegy is positioned as a shortcut to achieving clinical remission at this point.

Of course, it is important to make an early diagnosis and thoroughly understand the patient's symptoms.



We provide stable control of asthma!

Expect appropriate treatment to reduce exacerbations and asthma deaths ••

Case Sharing – Efforts towards Holistic Evaluation and Personalized Treatment of Asthma

Chang Gung Memorial Hospital; Linkou Branch
Department of Thoracic Medicine
Dr. Han-Chung Hu





Approach the Unmet Needs of Asthma

Who is responsible?







How to do?

Reason for uncontrolled asthma

Poor adherence

Trigger oversight

Poor inhalation technique

Comorbidities

Suboptimal medical care

Eur Respir Rev 2022; 31: 210176



Case Sharing: Experiences on the Path Toward Clinical Remission

曾敬閔 Ching-Ming Jimmy Tseng
Division of Chest Medicine, Cheng-Hsin General Hospital
School of Medicine, National Yang Ming Chiao Tung University
2025/8/30

PM-TW-FFV-PPTX-250093 Date of preparation: 2025.08 Trademarks are owned by or licensed to the GSK group of companies Relvar Ellipta was developed in collaboration with INNOVIVA. 不良事件通報程序: (02)23126836/oax40892@gsk.com 葛蘭素史克藥廠地址: 100台北市忠孝西路一段66號23樓



Intended for Taiwan Healthcare Professionals only

從控制到緩解 - Clinical Remission 氣喘治療新標竿

▼ Remission of asthma (GINA 2025)

目前尚未有一致的定義與標準,但通常指的是臨床緩解(與氣喘控制的長期目標一致)或完全緩解



臨床緩解

通常包含以下標準:

- 無氣喘症狀、無惡化
- 未使用口服類固醇
- 肺功能改善或維持



完全緩解

- 恢復氣道反應性 (airway responsiveness)
- 發炎反應標記恢復正常

Global initiative for asthma. 2025 Global Strategy for Asthma Management and Prevention. Available from: https://ginasthma.org/2025-gina-strategy-report/